Key Takeaways
- Strong FY22, but inventory overshadows: Revenue grew 29% YoY to ₹1,081 crore and EBITDA margins expanded to 29%, yet a deliberate, customer-driven inventory build added ~90 days, tying up cash and dominating the call.
- Pass-through contracts are the safety net: All products sit under contracts with raw-material price pass-through mechanisms, meaning the elevated inventory cost will ultimately be recovered from customers, protecting margins.
- Tanfac acquisition unlocks a fluorination future: The ₹148 crore stake purchase adds a platform with $200–260 million in medium-term topline potential, distinct from the existing ₹2,600 crore LOI book.
- Management refuses to pin down the unwind: Despite analyst pressure, the CFO declined to set a target for inventory-day normalization, citing extreme macro volatility and asking for patience for 1–2 quarters.
- What to watch next quarter: The pace at which high-cost inventory is billed and unwound, any progress on shifting contracts to 6-month pricing, and concrete CAPEX plans for the fluorination pipeline.
The Inventory Overhang
- A deliberate, customer-endorsed build: Inventory days rose ~90 days because European customers, anticipating shortages and price spikes after the Ukraine war began, explicitly directed Anupam to stockpile group derivatives to secure supply continuity.
- Cost recovery is contractual, not speculative: Every contract includes a raw-material price tolerance; once breached, the customer is immediately notified and must concur before Anupam proceeds, so the high-priced inventory is held with customer knowledge and acceptance.
- The unwind is a multi-quarter story: Management expects inventory to unwind over the next 2–4 quarters, with some improvement visible in a quarter or two but the bulk materializing later, assuming macro volatility subsides in 1–2 quarters.
- No target given: When asked whether inventory days would normalize closer to 200 days or lower, the CFO explicitly declined to peg any number, stating the world is too volatile to guide and asking analysts to wait 1–2 quarters for a concrete conversation.
Vishal Thakkar: "Today, the problem is that whatever I say, where the world moves, none of us really know well and hence I don't want to guide or even allude or indicate to anything which tomorrow we will have a conversation on that again. So, just wait for a quarter or two, let the things settle down and then we can have a more..."
Tanfac: The Fluorination Platform
- Acquisition completed: Anupam acquired a 25% stake from the Aditya Birla group for ₹148 crore, plus an additional 1% from the public via an open offer that closed on 6 May 2022; integration is underway with a top global consultancy, and IT and HR functions are already merged.
- Topline potential is separate and additive: Management sees a $200–260 million medium-to-long-term revenue opportunity from three key fluorination segments, especially fluoropolymers, over and above the existing ₹2,600 crore LOI book.
- Near-term CAPEX identified: At least ~₹50 crores in debottlenecking CAPEX for existing KF and HF capacity is planned for next year, with more to be sized once fluorination molecules are finalized with customers.
- Products will be high-value: Fluorination chemistry products are expected to carry higher margins and be more value-accretive than the current portfolio, though ramp-up will take time; 1–2 products may be manufacturable in existing capacity.
- Stake increase possible: The Government of Tamil Nadu / TIDCO holds an option to offer its Tanfac stake; Anupam would be happy to accept if offered.
Contract Structure & Pricing Shift
- Pass-through is the core defense: Every product operates under a contractual pass-through mechanism that covers raw-material price breaches, giving Anupam a structural shield against the 40–100%+ RM inflation seen on the crude side and ~30–40% on soda ash and caustic soda.
- Shift to 6-month pricing underway: Currently ~50% of customers have agreed to move from 12-month to 6-month pricing cycles; the remaining discussions are paused at customer request until volatility tapers, with management reasonably comfortable of achieving the shift over the next few quarters.
- Customer alignment on inventory: The elevated inventory was built in consonance with customers who are aware of both volume and price; their priority is supply-chain continuity, and they are comfortable carrying the cost.
Anand Desai: "As these products are under contract and all the contracts have a pass-through mechanism, every customer knows what prices they have agreed in the past year when we agreed on the price. In the meantime, there is a tolerance level for each price or each raw material price, and once that raw material tolerance is breached, we immediately inform the customer that this raw material price has breached now from the agreed ones and we would like to bring it to your notice, which is the mechanism built in within the contract."
Growth Engine & Diversification
- Five-year track record intact: Revenue CAGR of 26% over FY18–FY22 was driven by customer base expansion from 53 to 68 and product offerings from 25 to 48; management expects to continue a similar growth trajectory.
- LOI book provides visibility: The ₹2,600 crore combined LOI value is backed by a ₹250 crore FY23 CAPEX plan, with an expected asset turn of 1.75x and ROCE of 20%; peak revenue from these molecules is expected in FY25–26.
- New electronic-usage chemicals: One new product added for semiconductor manufacturing in 5G applications, plus ~4 products under development with a new US customer for electronic usage chemicals outside semiconductors.
- R&D investment deepening: The scientist headcount rose from 66 to 77 in Q4 alone, and a newly expanded R&D center commissioned in March 2022 can house 100 more professionals, signaling continued investment in the product pipeline.
Margins & Balance Sheet
- FY22 margin expansion: EBITDA margins improved from 26% to 29% and PAT margins from 8% to 14%, driven by operating leverage and the pass-through contract structure.
- Margin outlook is average, not peak: Management guided that historical margins of the last 2–3 years on average should continue, not the current quarter's margin; the CFO explicitly said he would not be aggressive on margin commitments.
- Debt to unwind with working capital: Working capital debt of ~₹200 crores should stabilize as inventory days reduce; promoter debt will be paid over 3 years and balance term debt over 5 years, with no significant additional debt expected for working capital growth.
- Receivables reclassification corrected: A wrong reclassification caused a mismatch between cash flow and balance sheet receivables; this was corrected in the consolidated balance sheet, where the number is ~₹70 crores.
Vishal Thakkar: "I would not want to be aggressive on my commitment here."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Continue historical ~26% CAGR trajectory | Over next time period (multi-year) |
| CAPEX deployment | ₹250 crores for LOI-linked expansion; asset turn of 1.75x, ROCE of 20% | FY23 |
| LOI conversion | LOIs under negotiation to conclude | 6 to 12 months |
| Peak revenue from new molecules | Bulk and significant revenue from latter half of ramp | FY25–26 |
| Inventory normalization | Improvement in inventory days to begin, assuming volatility reduces | H2 FY23 (conditional) |
| Contract pricing shift | Remaining ~50% of customers to move to 6-month pricing | Next few quarters |
| Tanfac CAPEX | ~₹50 crores for debottlenecking KF and HF capacity | Next year |
| Fluorination topline | $200–260 million potential, over and above LOI book | Medium to long term |
| Promoter debt repayment | Paid off | Over next 3 years |
| Term debt unwinding | Unwound | Over 5 years |
| Telecom/semiconductor validation | Validation and pilot runs continuing | ~9 months (until next March/February) |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Total revenues | ₹316.9 cr, +16% YoY |
| EBITDA including other revenues | ₹96.9 cr, +48% YoY |
| EBITDA margin | 31%, vs 26% in FY21 |
| Profit after tax | ₹46.1 cr, +108% YoY |
| Total revenues (FY22 full year) | ₹1,081.1 cr, +29% YoY |
| EBITDA (FY22 full year) | ₹311.2 cr, +42% YoY |
| EBITDA margin (FY22 full year) | 29%, vs 26% in FY21 |
| Profit after tax (FY22 full year) | ₹152.2 cr, +116% YoY |
| PAT margin (FY22 full year) | 14%, vs 8% in FY21 |
| Life sciences segment revenue (FY22) | ₹954.3 cr, 90% of total revenue |
| Other specialty chemicals segment revenue (FY22) | ₹108.6 cr, 10% of total revenue |
| Revenue CAGR (FY18–FY22) | 26% |
| ROCE (FY22) | 12%, vs 9% in FY18 |
| Installed capacity | 27,000 MT, >100% growth from 12,000 MT in FY18 |
| Product offerings | 48, +92% from 25 in FY18 |
| Number of customers | 68, from 53 in FY18 |
| R&D scientists | 77, up from 66 in Q3 FY22 |
| Top 10 customer revenue concentration | 80% of total revenue |
| LOI/contract total value | ₹2,600 cr over 5 years, peak annual revenue ~₹500 cr |
| FY23 CAPEX guidance | ₹250 cr, expected asset turn of 1.75x and ROCE of 20% |
| Working capital debt (year-end FY22) | ~₹200 cr |
| Tanfac stake acquired | 26%, 25% from Aditya Birla group for ₹148 cr plus 1% from public via open offer |
| Fluorination topline potential (medium to long term) | $100–200 mn per annum |
| Solar power investment | ₹27 cr for 7.5 MW plant, adding to 12.5 MW commissioned earlier |